
Gelesis Holdings Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $615
- Today's High:
- $643
- Open Price:
- $630.95
- 52W Low:
- $0.011
- 52W High:
- $1.3
- Prev. Close:
- $629.8
- Volume:
- 164657
Company Statistics
- Market Cap.:
- $11.63 million
- Book Value:
- -0.342
- Revenue TTM:
- $25.77 million
- Operating Margin TTM:
- -472.72%
- Gross Profit TTM:
- $1.20 million
- Profit Margin:
- -216.48%
- Return on Assets TTM:
- -60.99%
- Return on Equity TTM:
- -552.36%
Company Profile
Gelesis Holdings Inc had its IPO on 2022-01-13 under the ticker symbol GLS.
The company operates in the Healthcare sector and Biotechnology industry. Gelesis Holdings Inc has a staff strength of 93 employees.
Stock update
Shares of Gelesis Holdings Inc opened at $630.95 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of $615 - $643, and closed at $618.1.
This is a -1.86% slip from the previous day's closing price.
A total volume of 164,657 shares were traded at the close of the day’s session.
In the last one week, shares of Gelesis Holdings Inc have slipped by -1.09%.
Gelesis Holdings Inc's Key Ratios
Gelesis Holdings Inc has a market cap of $11.63 million, indicating a price to book ratio of 5.2308 and a price to sales ratio of 0.6262.
In the last 12-months Gelesis Holdings Inc’s revenue was $25.77 million with a gross profit of $1.20 million and an EBITDA of $-116318000. The EBITDA ratio measures Gelesis Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Gelesis Holdings Inc’s operating margin was -472.72% while its return on assets stood at -60.99% with a return of equity of -552.36%.
In Q1, Gelesis Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 9.1%.
Gelesis Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gelesis Holdings Inc’s profitability.
Gelesis Holdings Inc stock is trading at a EV to sales ratio of 4.7069 and a EV to EBITDA ratio of -0.5971. Its price to sales ratio in the trailing 12-months stood at 0.6262.
Gelesis Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $98.78 million
- Total Liabilities
- $49.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $224000
- Dividend Payout Ratio
- 0%
Gelesis Holdings Inc ended 2025 with $98.78 million in total assets and $0 in total liabilities. Its intangible assets were valued at $98.78 million while shareholder equity stood at $-26689000.00.
Gelesis Holdings Inc ended 2025 with $0 in deferred long-term liabilities, $49.38 million in other current liabilities, 7000.00 in common stock, $-327881000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.10 million and cash and short-term investments were $3.10 million. The company’s total short-term debt was $33,994,000 while long-term debt stood at $0.
Gelesis Holdings Inc’s total current assets stands at $25.42 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $14.11 million compared to accounts payable of $7.91 million and inventory worth $5.94 million.
In 2025, Gelesis Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $224000.
Comparatively, Gelesis Holdings Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $618.1
- 52-Week High
- $1.3
- 52-Week Low
- $0.011
- Analyst Target Price
- $0.45
Gelesis Holdings Inc stock is currently trading at $618.1 per share. It touched a 52-week high of $1.3 and a 52-week low of $1.3. Analysts tracking the stock have a 12-month average target price of $0.45.
Its 50-day moving average was $625.42 and 200-day moving average was $485.7 The short ratio stood at 3.37 indicating a short percent outstanding of 0%.
Around 5270.2% of the company’s stock are held by insiders while 2938.4% are held by institutions.
Frequently Asked Questions About Gelesis Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.